Company intelligence / Profile preview

Varsity Pharmaceuticals

Cambridge, England, United Kingdomvarsitypharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Varsity Pharmaceuticals is developing small molecule therapies targeting treatment-resistant cancers. Its lead program is a DNA polymerase theta inhibitor licensed from Dana-Farber Cancer Institute for HR-deficient tumors. All pipeline programs are currently in preclinical development. No clinical results have been reported as of June 2025.

Therapeutic areas: Oncology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

5 assets

VP-003

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Dana-Farber Cancer Institute (licensing partner for Novobiocin)

Beyond the preview

Go deeper on Varsity Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Varsity Pharmaceuticals.

Explore the full profile